Article

Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA.
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (impact factor: 4.55). 02/2007; 2(1):91-2. pp.91-2
Source: PubMed

ABSTRACT Bronchioalveolar carcinoma of the lung represents increasingly recognized clinical entity with relatively high probability of response to epidermal growth factor receptor tyrosine kinase inhibitors. Patients who respond to these agents eventually develop resistance. In this case report, we describe a patient who relapsed after gefitinib treatment and achieved unusual response to vinflunine single-agent chemotherapy, despite earlier progression to a combination of another vinca alkaloid and cisplatin. Molecular characterization of the primary tumor before any treatment is provided, and mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors are briefly discussed.

0 0
 · 
0 Bookmarks
 · 
27 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Bronchioalveolar carcinoma
 
case report
 
epidermal growth factor receptor tyrosine kinase inhibitors
 
Molecular characterization
 
Patients
 
primary tumor
 
unusual response
 
vinca alkaloid
 
vinflunine single-agent chemotherapy